Many methadone clinics test patients for THC and impose sanctions for positives. Federal rules don't require most of this, and it's unjustifiable. Natural Medicines, the Authority on Integrative Medicine Safety of Cannabidiol Given to Subject With Methadone or Buprenorphine The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid
Why Are Methadone Patients Still Being Punished for Marijuana Use?
M arijuana, which is now legal for medical use in 33 states and counting, can help treat pain — something which opioids also treat. But people with opioid use disorders (OUDs), including those getting treatment with methadone or buprenorphine, may have a hard time getting the pain relief they need (and these days, even people without OUDs have a hard time getting pain relief).
So why do so many treatment programs — including opioid treatment programs (OTPs, also known as methadone clinics) and office-based opioid treatment (OBOT) providers — test for tetrahydrocannabinol (THC), the psychoactive ingredient of cannabis?
Contradictions in Colorado
Even in Colorado, one of the first two states to legalize cannabis for recreational use, OTPs are required by state law to test for THC.
Treatment providers there are frustrated by this. Tina Beckley, regional director in Colorado for Behavioral Health Group , said recently that ever since Colorado started requiring OTPs to test for THC in 2006, many patients have lost their take-home doses —often, understandably, having thought that their medical marijuana card would spare them this sanction. Some decided to leave treatment as a result. It was a recipe for chaos and increased risk.
In Colorado, take-homes for people who receive medical marijuana are limited to those with no history of illicit marijuana use, who had a medical condition that was identified as being treatable with marijuana, and whose primary care providers agreed to the use of medical marijuana.
These problems began when only medical marijuana was permitted. With the advent of recreational marijuana in 2012, life for OTP patients — and providers — got even more complicated.
Methadone patients use nicotine and alcohol without sanctions, yet the same still doesn’t apply to state-legal marijuana. And this after many methadone patients, according to Beckley, moved to Colorado specifically for the marijuana.
What Federal Rules Say—And Don’t
Here’s the catch-22. If an OTP does test for THC, and the sample comes up positive, the OTP can’t necessarily just disregard it. Under some state and clinic rules, the OTP may take steps such as reducing the patient’s take-home doses.
But there’s no reason to do so, according to the federal guidelines .
Even though THC testing is frequently applied in some states, this testing is never federally mandated except at admission.
If methadone doesn’t show up in the toxicology reports, there is reason for concern—the patient may be diverting take-homes and foregoing the benefits of methadone. If barbiturates or benzodiazepines show up, there is also reason for concern because of risks to the patient. (But taking barbiturates, benzodiazepines, or other opioids in addition to methadone might mean that the patient is not getting high enough dose of methadone; it does not mean that the patient should be punished.)
There is, however, no evidence that cannabis combined with methadone is harmful. This is why, in the era of medical marijuana, there is little point in even testing for THC in OTPs, and in fact the federal government doesn’t recommend it after the patient’s first visit. Outmoded and outdated state regulations need to be fixed.
Even though THC testing is frequently applied in some states, this testing is never federally mandated except at admission. Both the federal Substance Abuse and Mental Health Services Administration (SAMHSA), and the Joint Commission, which together accredit and certify OTPs, say OTPs should only test patients for THC once — upon admission. A “Dear Colleague” letter from SAMHSA, which is equivalent to regulation, does not suggest that OTPs test for THC.
But there is pushback — don’t assume that the federal government supports cannabis for people with OUDs. The SAMHSA letter expresses plenty of concern about potential harms related to marijuana use. And while some states have decreed that cannabis can be used instead of opioid agonists to treat opioid use disorders, this has prompted SAMHSA head Elinore McCance-Katz, MD, PhD, as well as OTPs, to disagree.
According to the American Society of Addiction Medicine , however, in states where medical cannabis is legal, the same approaches should apply as are used for other medications. Indeed, other medications may cause some problems for patients taking methadone which cannabis does not cause.
A Psychiatrist Who Prescribes Buprenorphine and Cannabis
Leaving the situation of OTPs and methadone for a moment, let’s consider buprenorphine. It’s not only OTPs, which mainly dispense methadone, that are interested in helping patients by allowing cannabis.
Frederick E. Kahn, MD, a psychiatrist practicing with Forest Recovery in New Jersey, prescribes cannabis for pain in his buprenorphine patients (though patients can’t obtain a medical marijuana card from Forest; they need to have one already).
“If the piece of the withdrawal you’re experiencing is anxiety, maybe [cannabis] can help you.”
“One hundred percent of my patients became addicted to opioids because of having pain problems, mostly chronic,” he told Filter . Complaints included lower-back pain, lupus, neck injuries and autoimmune diseases, he said. In addition, he said some of his patients became addicted following acute pain — they were prescribed hundreds of pills of opioids after, for example, shoulder surgery.
Kahn said the cannabis doesn’t help opioid withdrawal specifically — there are other drugs for that — but it can treat anxiety in some patients. “If the piece of the withdrawal you’re experiencing is anxiety, maybe it can help you,” he said.
When beginning treatment for opioid use disorder with buprenorphine, his patients have adequate doses within the first 24 hours to treat their withdrawal, he said. Under-medication — a dose that’s not high enough—is responsible for patients feeling withdrawal symptoms, and should not occur with good treatment. This is not always the case with OTPs, which are required by law to start methadone on low doses regardless of the dose the patient will end up on.
Kahn does test his patients, including for THC. But he doesn’t use the results punitively. (And he’s not an OTP, so doesn’t have those federal regulations to deal with.)
“If someone is positive and we didn’t know about it, we talk about it with them, see what it’s doing or not doing for them,” said Kahn. “We work with them about it. Toxicology is not there to punish people. It’s there to help guide treatment.”
How does Kahn know that his patients are not, for example, using the cannabis addictively, but really need it for pain? “That comes from the doctor-patient relationship,” he said. “You can’t tell from the blood level.”
But you can discuss it. “Ask them how much they’re smoking. We can talk about changing from smoking to either vaping or making some kind of foodstuff because of [lung] problems with smoking anything,” he said. “You can talk about how many times they’re using it a day, how many puffs, how many grams.” The point is to make an active commitment to work together as doctor and patient, he said—and to bear in mind that most of these cannabis-using patients are on fewer opioids for pain.
At Forest, patients come in voluntarily. “Everybody’s in therapy, so we’re not just handing out buprenorphine — we’re following them closely,” he said.
People who work in New Jersey’s cannabis dispensaries usually consult with the patients about strains and potency. But Kahn described this set-up as “the Wild West.” They’re not pharmacists or doctors, he said, “they just work there.”
Contrasting Approaches in New York and Massachusetts
New York State does not require its OTPs to test for THC. Allegra Schorr, president of the Coalition of Medication-Assisted Treatment Providers and Advocates, the state’s membership association of OTPs, told Filter that there is a very mixed message going out to OTPs about cannabis. Schorr, who is married to Kahn, also heads West Midtown Medical Group, a proprietary OTP based in New York City.
“There’s enough evidence on chronic pain so that we should try this,” said Schorr of medical cannabis for OTP patients. “There are some conditions that we can easily find consensus on.”
And she commended the state’s regulatory agency, the Office of Alcoholism and Substance Abuse Services (OASAS), for not taking a hardline approach. Many other states have much to learn from this.
Massachusetts, by way of contrast, is another state that, like Colorado, requires THC testing in its OTPs.
“Conquering an opioid addiction is no easy feat for someone chemically handcuffed to narcotic medicines,” said Benjamin Caplan, MD, founder of the CED Foundation and a physician who treats patients at the CED clinic. “In states with medicinal cannabis as an option, we see strong evidence of better results for recovery from opiates: fewer prescriptions, better pain management, less suffering, and better quality of life.”
Peter Grinspoon, MD, has treated OUD patients with cannabis as well. He has a primary care practice affiliated with Massachusetts General Hospital. “In the almost-universal anecdotal experience of the patients I’ve treated, cannabis is the most effective medication for withdrawal symptoms from opioid addiction,” he told Filter . “Certainly better than clonidine and lofexidine. This is true whether they are or aren’t in OTP programs.”
“In my personal experience transitioning off of opiates,” he added, “I found cannabis to be profoundly helpful, particular in offsetting the physical symptoms of opiate withdrawal, as well as cravings and anxiety.”
Seeing Cannabis Use for What It Is
Among many studies on this issue, there have been these findings showing the benefits or lack of harms of cannabis for OTP patients:
Cannabis use does not negatively influence opioid outcomes among patients receiving buprenorphine maintenance treatment, with no difference in productivity and quality of life between individuals maintained on buprenorphine with and without current cannabis use.
For people who use drugs and start opioid agonist treatment, daily cannabis use was associated with a 21 percent greater odds of treatment retention compared with less-than-daily cannabis use.
Cannabis use dropped significantly following methadone dose stabilization , and data suggested that objective ratings of withdrawal symptoms decrease in methadone patients using cannabis during this stabilization period
It’s not that most OTPs necessarily want their patients to take cannabis; many do not. But it should be up to the program’s discretion, they say, not mandated by state or federal governments in terms of testing and sanctions such as loss of take-homes.
And emerging evidence that cannabis helps with opioid craving make it even more important to use judgment, and not hard-and-fast rules, about cannabis — especially during an opioid-involved overdose crisis.
Retention in treatment is much more important than keeping people off of cannabis, which — unlike, say, illicit fentanyl — isn’t responsible for any deaths.
CBD Oil And Methadone
A new report suggests that taking cannabidiol (CBD) might increase methadone levels and increase its side effects. This is especially concerning in chronic pain settings such as cancer.
A 13-year-old patient with chronic cancer pain who was previously stabilized on methadone 7.5 mg twice daily was admitted to the ER with opioid-related side effects. These side effects started 5 days prior to the ER visit, which occurred about 2 weeks after her parents increased her dose of CBD oil 4-fold. After stopping CBD, the side effects resolved. CBD may increase methadone levels by inhibiting the cytochrome P450 3A4 (CYP3A4) and CYP2C19 enzymes, which metabolize methadone. This is the first case report suggesting there is an interaction between CBD and methadone. The interaction appears to be dose-dependent – in this case, it occurred with a very high dose of CBD but not with a much lower dose. More evidence is needed to verify this interaction and to determine the CBD dose threshold at which it might occur.
Many patients and their families don’t disclose the use of natural medicines such as CBD and other cannabis products to their healthcare providers. It’s important to discuss the use of all cannabis-derived products with patients and their families. Healthcare providers should ask directly about CBD use and be aware of its potential drug interactions.
- Does CBD Help with Chronic Pain?
- CBD for opioid withdrawal?
- Cannabidiol: What you need to know
- Is CBD Safe During Pregnancy?
The information in this brief report is intended for informational purposes only, and is meant to help users better understand health concerns. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions. Copyright © 2022 Natural Medicines Inc. Commercial distribution or reproduction prohibited. Natural Medicines is the leading provider of high-quality, evidence-based, clinically-relevant information on natural medicine, dietary supplements, herbs, vitamins, minerals, functional foods, diets, complementary practices, CAM modalities, exercises and medical conditions. Monograph sections include interactions with herbs, drugs, foods and labs, contraindications, depletions, dosing, toxicology, adverse effects, pregnancy and lactation data, synonyms, safety and effectiveness.
Safety of Cannabidiol Given to Subject With Methadone or Buprenorphine
The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain. This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in outpatients with OUD receiving medication-assisted treatment (MAT) with methadone or buprenorphine.
|Condition or disease||Intervention/treatment||Phase|
|Addiction||Drug: CBD Day 1 Drug: CBD Day 2 Drug: CBD Day 3||Early Phase 1|
An initial safety pilot phase will recruit six participants: three receiving treatment with methadone and three receiving treatment with buprenorphine. If the results of the pilot study support the safety of CBD administration in this clinical sample, the general study will recruit 48 participants with comorbid OUD and chronic pain, for a total of 24 completers – 12 subjects (6 men and 6 women) receiving methadone and 12 subjects (6 men and 6 women) receiving buprenorphine. Both sub-studies will enroll participants who do not currently require an inpatient hospitalization.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||6 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||Initial safety pilot phase of 6 participants,(3 methadone and 3 on Buprenorphine) The general study is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in outpatients with OUD receiving medication-assisted treatment (MAT) with methadone or buprenorphine.|
|Masking:||None (Open Label)|
|Official Title:||Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain|
|Actual Study Start Date :||December 8, 2021|
|Estimated Primary Completion Date :||April 30, 2023|
|Estimated Study Completion Date :||July 30, 2023|
Pain Threshold [ Time Frame: 4 measurements per test day, 3 total test days ]
The Cold Pressor (CPT measures Pain threshold (in seconds). For this test, a cooler filled with cold water (32.9-34.7degrees F/0.5-1.5 degrees C) are used. Participants are instructed to immerse their hand into the water and report the first time they experience pain (pain threshold). Lower scores indicate lower pain threshold. Minimum score is 0 seconds, and a maximum cut-off score of 300 seconds is used to prevent tissue damage.
The Cold Pressor Test (CPT) measures pain threshold and pain tolerance (in seconds). For this test, a water cooler is filled with cold water (32.9-34.7ºF/0.5-1.5ºC) are used. To begin the CPT, Participants are then instructed to immerse their hand into the cold water bath and report when the pain becomes unbearable (pain tolerance). Lower scores indicate lower pain tolerance. Minimum score is 0 seconds, and a maximum cut-off score of 300 seconds is used to prevent tissue damage.
The QST is a reliable, dynamic, and computerized method of quantifying distinct mechanisms of the pain experience
The QST is a reliable, dynamic, and computerized method of quantifying distinct mechanisms of the pain experience
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Males and females, Veterans and non-Veterans, aged between 18 and 70 years old.
- Diagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance treatment.
- Having chronic pain, uniformly operationalized as grade II (high-intensity) non- cancer pain for ≥ 6 months 49.
- Capable of providing informed consent in English.
- Compliant in opioid maintenance treatment and on a stable dose for four weeks or longer.
- Not meeting DSM-5 criteria for substance use disorders other than OUD or tobacco use disorder within the last 12 months.
- No current medical problems deemed contraindicated for participation by principal investigator.
- For women, not pregnant as determined by pregnancy screening; not breast-feeding; using acceptable birth control methods. Acceptable contraception for females includes oral contraceptives, contraceptive depot injections, contraceptive subdermal implants, intrauterine devices, or surgical contraception methods. Acceptable contraception for males includes condoms or surgical contraception methods.
- Other current major psychiatric disorders deemed clinically unstable by the principal investigator, such as severe depression and/or active suicidal ideation.
- Having experienced major psychosocial stressors recently (≤ 6 weeks before enrollment), at the discretion of the principal investigator.
- Methadone dose under 60mg or over 100mg
- Buprenorphine over 24mg.
- Having received inpatient psychiatric treatment recently (≤ 60 days before enrollment).
- Candidates receiving products containing either THC or CBD will be excluded.
- Current use regular use other prescription opioids, gabapentinoids (pregabalin, gabapentin), antidepressants (SSRIs, SNRIs, TCAs), benzodiazepines, platelet inhibitors (e.g., clopidogrel, apixaban, ticagrelor), or NSAIDs.
- Current weight of less of 60 kg.
- Allergy to sesame seed oil, which is an ingredient of the CBD formulation used.
- Serious medical or neurological illness or treatment for a medical disorder that could interfere with study participation as determined by principal investigator.
- Participants who have elevation of liver enzymes (ALT and/or AST) 2x above the normal limit or higher.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05076370